The easy-to-use online resource mHealth Roadmap includes information on implementation guidelines for mobile and mHealth strategies and applications. Topics covered in the Healthcare Information and Management Systems Society (HIMSS) mHealth Roadmap include:

GE Healthcare has announced U.S. Food and Drug Administration (FDA) approval of SenoClaire, GE’s new breast tomosynthesis solution designed with three-dimensional imaging technology. In collaboration with Massachusetts General Hospital, GE developed SenoClaire technology that uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a “step-and-shoot” method, removing the potential motion from the tube, helping to reduce blur and increase image sharpness.

September 2, 2014 — GE Healthcare announced that the Vizamyl flutemetamol (18F) solution for injection has received marketing authorization from the European Commission as a radiopharmaceutical medicinal product indicated for positron emission tomography (PET) imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment.

September 2, 2014 — In an agreement signed in Tokyo, Elekta Japan will grant Toshiba Medical Systems Corp. (TMSC) wider distribution rights regarding linear accelerator (linac) sales. The agreement builds on a sales and marketing agreement from 2010.

Philips has launched Affiniti. The new ultrasound system made its debut at the European Society of Cardiology (ESC) Congress 2014 in Barcelona.

Study Confirms CT Lung Cancer Screening is Cost-Effective: Full Medicare Coverage Should Follow, Says ACR

September 2, 2014 — An actuarial cost-benefit analysis published in the August issue of American Health and Drug Benefits shows that use of U.S. Preventive Services Task Force (USPSTF) lung cancer screening recommendations in high-risk Medicare beneficiaries is cost-effective, potentially answering any questions regarding the effectiveness, infrastructure and cost effectiveness of low-dose computed tomography (CT) screening.

The evidence standard the Centers for Medicare & Medicaid Services (CMS) used to approve Medicare coverage of a stool DNA colorectal cancer (CRC) screening test — under a new joint approval process with the U.S. Food and Drug Administration (FDA) — should be applied to CT colonography (virtual colonoscopy) and other CRC screening exams according to the American College of Radiology (ACR). In a new letter to CMS, ACR urged coverage criteria be transparent and consistently applied.

The high demand for qualified health IT professionals continues, as revealed in the 2014 HIMSS Workplace Study, conducted by HIMSS Analytics. The study shows more than 84 percent of survey respondents reported their organization hired at least one staff member in the past year, a finding consistent with the 2013 survey (86 percent). With hiring in 2014 expected to continue at the 2013 pace, 82 percent of survey respondents planned to hire at least one full-time employee (FTE) in the next 12 months, a slight increase from the 79 percent of respondents planning the same in 2013.

Kit Lam and colleagues from UC Davis and other institutions have created dynamic nanoparticles (NPs) that could provide an arsenal of applications to diagnose and treat cancer. Built on an easy-to-make polymer, these particles can be used as contrast agents to light up tumors for magnetic resonance imaging (MRI) and positron emission tomography (PET) scans or deliver chemo and other therapies to destroy tumors. In addition, the particles are biocompatible and have shown no toxicity. The study was published online in Nature Communications.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now